Osteoporosis and diabetes

被引：74

作者：

Diane L. Chau

Steven V. Edelman

Manju Chandran

机构：

[1] Department of Geriatric Medicine, VA Sierra Health Care Systems, Univ. of Nevada School of Medicine, Reno, NV 89502

来源：

Current Diabetes Reports | 2003年 / 3卷 / 1期

关键词：

Bone Mineral Density; Osteoporosis; Alendronate; Zoledronic Acid; Raloxifene;

D O I：

10.1007/s11892-003-0051-8

中图分类号：

学科分类号：

摘要：

Osteoporosis is the most prevalent metabolic bone disease in the United States. Although the disease has historically been reported mostly in white women, it can affect individuals of both sexes and all ethnic groups. The presence of osteoporosis related to diabetes is not well acknowledged and the impact of osteoporosis in a diabetic patient is often not considered. Routine screening or initiation of preventive medications for osteoporosis in all patients with type 1 or type 2 diabetes is not recommended at the present time. However, in all patients with diabetes, besides optimal glycemic control, general recommendations regarding adequate dietary calcium intake, regular exercise, and avoidance of other potential risk factors such as smoking should be given. In patients who have positive risk factors for osteoporosis, or in those who present with fractures, evaluation of bone density should be done and respective preventive or therapeutic interventions should be applied. Copyright © 2003 by Current Science Inc.

引用

页码：37 / 42

页数：5

共 49 条

[31] Ettinger B., Black D.M., Mitlak B.H., Et al., Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial, JAMA, 282, pp. 637-645, (1999)
[32] Taranta A., Brama M., Teti A., Et al., The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro, Bone, 30, pp. 368-376, (2002)
[33] Andersson B., Johannsson G., Holm G., Et al., Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: A randomized clinical trial, J. Clin. Endocrinol. Metab., 87, pp. 122-128, (2002)
[34] Chesnut III C.H., Silverman S., Andriano K., Et al., A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study, Am. J. Med., 109, pp. 267-276, (2000)
[35] Young A.A., Wang M.W., Gedulin B., Et al., Diabetogenic effects of salmon calcitonin are attributable to amylin-like activity, Metabolism, 44, pp. 1581-1589, (1995)
[36] Starke A., Keck E., Berger M., Zimmermann H., Effects of calcium and calcitonin on circulating levels of glucagon and glucose in diabetes mellitus, Diabetologia, 20, pp. 547-552, (1981)
[37] Black D.M., Cummings S.R., Karpf D.B., Et al., Randomized trial of alendronate on risk of fracture in women with existing vertebral fractures, Lancet, 348, pp. 1535-1541, (1996)
[38] Harris S.T., Watts N.B., Genant H.K., Et al., Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial, JAMA, 282, pp. 1344-1352, (1999)
[39] Thiebaud D., Burckhardt P., Melchior J., Et al., Two years effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause, Osteoporosis Int., 4, pp. 76-83, (1994)
[40] Thiebaud D., Burckhardt P., Kriegbaum H., Et al., Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis, Am. J. Med., 103, pp. 298-307, (1997)

← 1 2 3 4 5 →